



Supplementary Figure 1




Supplementary Figure 1| Folate cycle enzymes contribute to tumour resistance against cytotoxic T cells. **a**, 72 genes were identified that the sgRNAs of which decreased in T cell group (Z-score(T) < -3, P < 0.1), 3878 over-expressed genes were selected in human tumors (Z-score > 3) from a previous meta-analysis (also see Supplementary Data 1 and 2). Among them, 19 genes up-regulated in tumours were selected and listed in the table. **b**, Schematic diagram of MTHFD2 in the mitochondria and cytoplasm. **c**, Relative mRNA levels of MTHFD2 in SW1990 with siRNAs were analyzed by real-time PCR. (n=3 independent experiments) **d**, LDH release in SW1990 with MTHFD2 siRNAs. (n=4 independent experiments) **e**, mRNA level of MTHFD2 in indicated cell lines were analyzed by real-time PCR. (n=3 independent experiments) **f-g**, MTHFD2 protein in SW1990 cells stably with indicated sgRNAs (**f**) and Pan02 cells with indicated shRNAs (**g**) were analyzed by immunoblotting. **h**, mRNA levels of MTHFD2 in indicated cells transfected with MTHFD2 siRNAs were analyzed by real-time PCR. (n=3 independent experiments) **i**, LDH release in indicated cells transfected with MTHFD2 siRNAs. (n=3 independent experiments) In **c-e**, **h** and **i**, the values are presented as mean ± s.e.m., P value represented (Student's t-test, two-sided) with control or the indicated groups.

Supplementary Figure 2



Supplementary Figure 2 | MTHFD2 promotes tumour immune evasion via upregulating PD-L1 expression. **a**, Spearman's correlation between PD-L1 and MTHFD2 in Pancreatic cancer clinical samples from TCGA database. **b**, PD-1 expression were detected by immunoblotting in CD8⁺ T cells activated by 2 μ g/ml CD3, CD28 and 10 ng/ml IL-2 for 24 hours. **c**, SW1990 cells wildtype or MTHFD2 KO cells expressing PD-L1, were incubated with activated human CD8⁺ effector T cells for 16 hours and the cytotoxicity were measured by LDH release assay. (n=7 independent experiments) **d**, Real-time Cell index analysis in WT or MTHFD2-KO SW1990 cells transfected with indicated expressing vectors, were incubated with activated human CD8⁺ T-cells in xCELLigence Plates. **e**, PD-L1 protein were analyzed by immunoblotting in SW1990 cells transfected with PD-L1 siRNA. In **c**, the values are presented as mean \pm s.e.m., P value represented (Student's t-test, two-sided) with control or the indicated groups.


Supplementary Figure 3



Supplementary Figure 3| MTHFD2 is induced by IFN- γ and involved in IFN- γ -mediated PD-L1 regulation.


a, PD-L1 protein in indicated cells were analyzed by immunoblotting. **b**, p-AKT(S473) were analysed in SW1990 treated with AKT inhibitor LY294002 10 μ M for 24 hours. **c-d**, SW1990 cells transfected with indicated siRNAs for 24 hours and then treated with 20 ng/ml IFN- γ for another 24 hours (**c**), or 20, 50 μ M Fludara with 20 ng/ml IFN- γ for 24 hours (**d**), immunoblotting analyses were performed using the indicated antibodies. **e**, p-mTOR(S2448) and p-S6K1(T389) were analysed in SW1990 treated with rapamycin 100 nM for 24 hours. **f-h**, SW1990 cells transfected with indicated siRNAs for 24 hours and then treated with 20 ng/ml IFN- γ (**f-h**), 100nM rapamycin (**f**) or 20 μ M Fludara (**h**) for another 24 hours, immunoblotting analyses were performed using the indicated antibodies. **i**, SW1990 cells treated with 20 ng/ml IFN- γ for indicated times, immunoblotting analyses were performed using the indicated antibodies. **j**, A model showing the regulatory relationships among IFN- γ , MTHFD2 and PD-L1 with known and unknown mechanisms.

Supplementary Figure 4




Supplementary Figure 4| Metabolic function of MTHFD2 promotes protein PD-L1 transcription through uridine-related-metabolites. a-f, SW1990 cells were treated with indicated concentration of indicated metabolites for 24 hours, immunoblotting analyses were performed using the indicated antibodies. SAM for S-adenosylmethionine, NAM for nicotinamide.

Supplementary Figure 5



Supplementary Figure 5| Protein O-GlcNAcylation mediates MTHFD2 and uridine-related-metabolites enhanced PD-L1 transcription. a-b, SW1990 cells transfected with indicated siRNAs or indicated expressing vectors, or treated by 2.5, 25 mM glucose for 24 hours, immunoblotting analyses were performed using the indicated antibodies. c, SW1990 cells transfected with indicated expressing vectors, PD-L1 mRNA levels were analyzed by real-time PCR. (n=3 independent experiments) In c, the values are presented as mean \pm s.e.m., **represents $p < 0.01$ (Student's t-test, two-sided) with vec group.

Supplementary Figure 6




Supplementary Figure 6| MTHFD2 promotes PD-L1 transcription through cMYC O-GlcNAcylation. **a-b**, SW1990 cells transfected with indicated siRNAs or indicated expressing vectors, immunoblotting analyses were performed using the indicated antibodies. **c**, SW1990 cells transfected with indicated expressing vectors, the transcriptional activity of PD-L1 promoter (from -2000 bp to 0 bp) is examined by a luciferase-based reporter assay (n=5 independent experiments); immunoblotting analyses were performed using the indicated antibodies. **d**, SW1990 cells transfected with MTHFD2 siRNA, cMYC mRNA levels were analyzed by real-time PCR. (n=3 independent experiments) **e**, Analysis of the apparent half-life time of wild-type and mutant cMYC in cycloheximide treated cells transfected with indicated vectors. (n=3 independent experiments) In c-e, the values are presented as mean \pm s.e.m., P value represented (Student's t-test, two-sided) with control or the indicated groups.


Supplementary Figure 7

a


Blank




Con siRNA



MTHFD2 siRNA




MTHFD2 siRNA/PD-L1




b


Blank




Con shRNA



MTHFD2 shRNA



MTHFD2 shRNA/PD-L1



Supplementary Figure 7 | Flow cytometry analysis of SW1990 cells in main Fig 2f and tumor tissues in C57 mice in main Fig 7f. **a left, Gating based on FSC-A and SSC-A of SW1990 cells with indicated treatment were shown. **a right**, The cell-membrane localized PD-L1 in SW1990 cells with indicated treatment were shown in histogram. **b left**, Cells digested from indicate tumour tissues in C57 mice were gated based on FSC-A and SSC-A. **b right**, Cells digested from indicate tumour tissues in C57 mice were stained with anti-CD45 antibody and displayed in histogram.**